| Autor: |
Dannemann C; Klinik und Poliklinik für Kiefer- und Gesichtschirurgie, UniversitätsSpitaL Zürich. christine.dannemann@usz.ch, Grätz KW, Zwahlen RA |
| Jazyk: |
French; German |
| Zdroj: |
Schweizer Monatsschrift fur Zahnmedizin = Revue mensuelle suisse d'odonto-stomatologie = Rivista mensile svizzera di odontologia e stomatologia [Schweiz Monatsschr Zahnmed] 2008; Vol. 118 (2), pp. 113-23. |
| Abstrakt: |
Since four years from now on more and more information about bisphosphonate induced osteonecrosis of the jaws is published not only in professional journals, but also in the mass media. The result is a growing uncertainty of patients, but also professionals in dealing with this group of medication. Usually bisphosphonates are prescribed for treatment of severe osteoporosis, but also for treatment of metastatic bone disease and tumor induced hypercalcemia. The following article gives information about bisphosphonates, bisphosphonate induced osteonecrosis of the jaws (BON) and potential risk factors. Additionally it shows the typical clinical picture, necessary diagnostic measures and informs about possible prevention strategies especially for dentists in daily practice. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
